Clinical Trial Update: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) [Phase 3]

View source ↗

Summary

Phase 3 LEAP-017 study evaluating lenvatinib plus pembrolizumab versus standard-of-care in metastatic colorectal cancer has completed enrollment and posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2024-04-09